BioNTech SE (BNTX) Price & Analysis

Compare

4,581 Followers

BNTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$76.53 - $131.49

Previous CloseN/A

Volume316.50K

Average Volume (3M)1.41M

Market Cap

$27.80B

Enterprise ValueN/A

Total Cash (Recent Filing)$16.78B

Total Debt (Recent Filing)€254.20M

Price to Earnings (P/E)―

Beta0.87

Next Earnings

Aug 04, 2025

EPS Estimate

-2.41

Last Dividend Ex-Date

Jun 02, 2022

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.98

Shares Outstanding240,392,620

10 Day Avg. Volume1,372,306

30 Day Avg. Volume1,414,394

Financial Highlights & Ratios

PEG Ratio0.79

Price to Book (P/B)1.09

Price to Sales (P/S)0.00

P/FCF Ratio-100.16

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$139.35

Price Target Upside25.38% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering19

Bulls Say, Bears Say

Bulls Say

Financial PerformanceThe agreement with Bristol Myers Squibb gives BioNTech $3.5 billion in upfront and near-term cash, plus $7.6 billion in potential milestones, positioning BioNTech as an equal partner.

Research And DevelopmentBristol's extensive clinical operations in the US should significantly accelerate BNT327 development, providing a key advantage over competitors.

Strategic PartnershipBioNTech's deal with Bristol Myers Squibb is highly positive and offers continued upside by maximizing the value of BNT327.

Bears Say

Market ConfidenceWith overall survival benefits not as great in magnitude, the market may want to see more global data in various settings to gain confidence in the broadest possible commercial opportunity.

Trial Results UncertaintySummit's HARMONi study of ivonescimab in 2L EGFR mut non-small-cell lung cancer did not meet statistical significance for overall survival, which is seen as a powering issue, with limited impact on BNT327.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

0.49% Insiders

5.06% Mutual Funds

13.11% Other Institutional Investors

80.38% Public Companies and Individual Investors

Detailed Ownership Overview >

BNTX FAQ

What was Biontech Se Sponsored Adr’s price range in the past 12 months?

Biontech Se Sponsored Adr lowest stock price was $76.53 and its highest was $131.49 in the past 12 months.

What is Biontech Se Sponsored Adr’s market cap?

Biontech Se Sponsored Adr’s market cap is $27.80B.

When is Biontech Se Sponsored Adr’s upcoming earnings report date?

Biontech Se Sponsored Adr’s upcoming earnings report date is Aug 04, 2025 which is in 59 days.

How were Biontech Se Sponsored Adr’s earnings last quarter?

Biontech Se Sponsored Adr released its earnings results on May 05, 2025. The company reported -$1.977 earnings per share for the quarter, beating the consensus estimate of -$2.617 by $0.64.

Is Biontech Se Sponsored Adr overvalued?

According to Wall Street analysts Biontech Se Sponsored Adr’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Biontech Se Sponsored Adr pay dividends?

Biontech Se Sponsored Adr pays a Notavailable dividend of $1.534 which represents an annual dividend yield of N/A. See more information on Biontech Se Sponsored Adr dividends here

What is Biontech Se Sponsored Adr’s EPS estimate?

Biontech Se Sponsored Adr’s EPS estimate is -2.41.

How many shares outstanding does Biontech Se Sponsored Adr have?

Biontech Se Sponsored Adr has 240,392,620 shares outstanding.

What happened to Biontech Se Sponsored Adr’s price movement after its last earnings report?

Biontech Se Sponsored Adr reported an EPS of -$1.977 in its last earnings report, beating expectations of -$2.617. Following the earnings report the stock price went down -3.659%.

Which hedge fund is a major shareholder of Biontech Se Sponsored Adr?

Currently, no hedge funds are holding shares in BNTX

BioNTech SE Stock Smart Score

Neutral

Fundamentals

Return on Equity

-3.87%

Trailing 12-Months

Asset Growth

-4.81%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Biontech Se Sponsored Adr

BioNTech SE is a German biotechnology company that specializes in developing and producing immunotherapies for the treatment of cancer and other serious diseases. The company is at the forefront of messenger RNA (mRNA) technology and has been instrumental in the development of vaccines, particularly its notable collaboration with Pfizer to produce a COVID-19 vaccine. BioNTech's core products focus on personalized cancer treatments, infectious disease vaccines, and regenerative medicines.

BNTX Company Deck

BNTX Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflects a company that is making significant progress in its oncology programs and maintaining a strong financial position, despite experiencing decreased revenue and a higher net loss. The strategic investments in developing new therapies and preparing for future product launches are promising, but the financial losses and settlement expenses are notable challenges.Read More>

BNTX Stock 12 Month Forecast

Average Price Target

$139.35

▲(25.38%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"77":"$77","182":"$182","103.25":"$103.3","129.5":"$129.5","155.75":"$155.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":181,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$181.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":139.35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$139.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$110.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[77,103.25,129.5,155.75,182],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.1,118.32307692307691,123.54615384615384,128.76923076923077,133.9923076923077,139.2153846153846,144.43846153846152,149.66153846153844,154.8846153846154,160.1076923076923,165.33076923076922,170.55384615384617,175.77692307692308,{"y":181,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.1,115.11923076923077,117.13846153846153,119.1576923076923,121.17692307692307,123.19615384615383,125.21538461538461,127.23461538461538,129.25384615384615,131.27307692307693,133.2923076923077,135.31153846153845,137.33076923076922,{"y":139.35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.1,112.86153846153846,112.62307692307692,112.38461538461539,112.14615384615384,111.9076923076923,111.66923076923077,111.43076923076923,111.1923076923077,110.95384615384616,110.71538461538461,110.47692307692307,110.23846153846154,{"y":110,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":100.6,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.83,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.68,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.22,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.93,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >